NFA
ESPR

Nationwide Fund Advisors’s Esperion Therapeutics ESPR Stock Holding History

Nationwide Fund Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,952
Closed -$1.15M – 666
2017
Q3 		$1.15M Sell
22,952
-26,347
-53% -$1.27M ﹤0.01% 1704
2017
Q2 		$2.28M Buy
49,299
+10,013
+25% +$368K 0.01% 1370
2017
Q1 		$1.39M Buy
39,286
+921
+2% +$21.1K 0.01% 1580
2016
Q4 		$480K Sell
38,365
-1,300
-3% -$15.5K ﹤0.01% 2193
2016
Q3 		$549K Buy
39,665
+3,801
+11% +$43.1K ﹤0.01% 2136
2016
Q2 		$354K Buy
35,864
+18,100
+102% +$300K ﹤0.01% 2328
2016
Q1 		$300K Hold
17,764
– – ﹤0.01% 2342
2015
Q4 		$395K Buy
17,764
+6,251
+54% +$158K ﹤0.01% 2234
2015
Q3 		$272K Buy
11,513
+3,000
+35% +$188K ﹤0.01% 2413
2015
Q2 		$696K Buy
8,513
+3,852
+83% +$377K ﹤0.01% 2061
2015
Q1 		$432K Buy
4,661
+131
+3% +$8.45K ﹤0.01% 2306
2014
Q4 		$183K Buy
4,530
+1,032
+30% +$31.6K ﹤0.01% 2678
2014
Q3 		$86K Hold
3,498
– – ﹤0.01% 3026
2014
Q2 		$55K Sell
3,498
-137
-4% -$1.98K ﹤0.01% 3094
2014
Q1 		$55K Hold
3,635
– – ﹤0.01% 2844
2013
Q4 		$50K Buy
3,635
+2,360
+185% +$34.3K ﹤0.01% 3064
2013
Q3 		$24K Buy
+1,275
New +$21.4K ﹤0.01% 3085

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nationwide Fund Advisors's ESPR Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 22,952 shares — an estimated $1.15M sold.

Nationwide Fund Advisors first reported a position in ESPR in Q3 2013 and held it in 17 quarters. The position peaked at $2.28M in Q2 2017. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 22,952 Esperion Therapeutics shares in Q4 2017, an estimated $1.15M.
  • Nationwide Fund Advisors first reported a position in Esperion Therapeutics in Q3 2013 and held it in 17 quarters.
  • Nationwide Fund Advisors's Esperion Therapeutics position peaked at $2.28M in Q2 2017.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.